Shonan Beauty Clinic Named to Newsweek’s “World’s Best Hospitals & Clinics for Medical Tourism 2027”
5.11.2026 16:00:00 EET | Business Wire | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced that Shonan Beauty Clinic, one of the clinic brands it supports, has been named to “World’s Best Hospitals & Clinics for Medical Tourism 2027,” an international ranking presented by Newsweek in partnership with Statista. The clinic was recognized in the Plastic & Reconstructive Surgery field, in both the liposuction and breast augmentation categories. The ranking covers six specialty fields across 13 countries. Within Plastic & Reconstructive Surgery, which comprises breast augmentation, liposuction, and rhinoplasty, each of the three categories names the top 75 institutions, and Shonan Beauty Clinic was recognized in two.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105535025/en/
Shonan Beauty Clinic Named to Newsweek’s “World’s Best Hospitals & Clinics for Medical Tourism 2027”
Highlights
- Global recognition: Shonan Beauty Clinic named to Newsweek’s inaugural “World’s Best Hospitals & Clinics for Medical Tourism 2027,” recognized in two of the three Plastic & Reconstructive Surgery categories, liposuction and breast augmentation
- Selective field: Chosen among leading institutions across 13 countries and six specialty fields; within Plastic & Reconstructive Surgery, each category names only the top 75 institutions
- Independent assessment: Evaluation is led by recommendations from physicians and medical peers, who may not recommend their own institutions
- Competitive moat: Underpinned by an in-house platform for international customer care that SBC Medical has built and scaled across its group, not easily replicated
- Proven demand: Visits by customers from overseas grew approximately 1.9 times from Q1 to Q3 2026, in a global medical tourism market projected to reach USD 250 billion by 2034 (23.3% CAGR)
The ranking evaluates institutions on their ability to serve patients traveling across borders for care, a segment expanding worldwide. Assessment draws on recommendations from physicians, healthcare professionals, and medical tourism facilitators across the covered countries; international accreditations; patient reviews and online reputation; and the strength of support services for international patients such as interpretation and translation. Recommendations from medical peers form the core of the evaluation.
The recognition reflects a foundation SBC Medical has built across its group, together with trust accumulated within the medical community. Rather than leaving these efforts to individual clinics, the Company has designed and operated them centrally, expanding their scope in stages, which underpins this international recognition.
Trust built within the medical community
In 2025, 33 physicians from Shonan Beauty Clinic took the podium at 28 academic conferences in Japan and abroad to present their research. Beyond presenting, many served as session chairs or helped shape academic programs. Sharing clinical insight at conferences and returning external expertise to daily practice, this cycle has strengthened the Company’s standing and trust within the medical community.
A reception platform built in-house, scaled step by step
The global medical tourism market is projected to grow at an average of 23.3% annually from 2026 to 2034, reaching approximately USD 250 billion by 2034 (source: Fortune Business Insights). SBC Medical has built its platform for capturing this demand in-house, rather than relying on outside vendors. In late 2025, it first focused on English-capable clinics, developing an English-language website and booking flow and testing them in live operation. Building on the results, in 2026 it rolled out “Talk Bridge,” an AI interpretation application purpose-built for aesthetic healthcare, across all clinics, enabling English-language support even where interpreters are not on site. It also established an in-house interpretation center (Chinese and English) and a specialist role, the Global Beauty Advisor, covering Japanese, Chinese, and English. Starting from a limited set of clinics and expanding once results were confirmed, the Company has built an integrated, in-house platform spanning language support, acquisition, and service. The results are visible in the numbers: from the first to the third quarter of 2026, visits by customers from overseas¹ grew approximately 1.9 times.
This platform and track record are a competitive advantage not easily replicated. Procedures such as liposuction and breast augmentation, which are more invasive, require robust systems for postoperative follow-up and for responding to any complications. Shonan Beauty Clinic maintains a 24-hour medical interpretation line that connects customers to the attending physician in case of postoperative concerns or changes in condition, and the interpretation center is progressively expanding its capacity to handle interpretation for such aesthetic surgical procedures.
Scalability through group-wide deployment and global application
This platform is not confined to any single clinic. Designed and operated by headquarters and deployed across the group, it allows clinics nationwide to maintain the same standard of customer reception. The operational know-how and talent developed through inbound care in Japan form a foundation the Company can apply to its global expansion in the United States and Asia. By further advancing the use of AI in interpretation and operational support, SBC Medical will raise the quality and efficiency of customer reception and strengthen this platform at an accelerating pace.
Ranking Overview
Name: World’s Best Hospitals & Clinics for Medical Tourism 2027
Presented by: Newsweek (research conducted by Statista)
Publication date: November 3, 2026 (U.S. time)
Countries covered: 13 (United States, Japan, South Korea, Thailand, Singapore, Malaysia, Turkey, Mexico, Brazil, Germany, Spain, Saudi Arabia, United Arab Emirates)
Evaluation period: September 3, 2025 - September 2, 2026
Specialty fields: 6 (Bariatric Surgery; Cancer Care; Cardiac Care & Cardiac Surgery; Ophthalmology; Orthopedics; Plastic & Reconstructive Surgery)
Categories recognized: Plastic & Reconstructive Surgery, liposuction and breast augmentation
Listed name: Shonan Beauty Clinic (Shinjuku, Japan)
¹ Total visits by overseas-resident customers to Shonan Beauty Clinic locations in Japan supported by the Company.
Comments
Yoshiyuki Aikawa, CEO, SBC Medical Group Holdings Incorporated
“More and more people are crossing borders to choose medical care in Japan, and ensuring they leave feeling it was the right choice is our starting point. We see this recognition as acknowledgment of what our clinics have built day by day, bridging language barriers and meeting each customer with sincerity. Drawing on clinical data and expertise cultivated across more than 280 clinics, we are turning that knowledge into medical AI so that anyone, wherever they come from, can access care of the same quality. Delivering reassurance beyond language and borders, and ultimately helping extend people’s healthy lifespan, we intend to remain a longevity company.”
Hiroyuki Miya, COO, SBC Medical Group Co., Ltd.
“Being understood in one’s own language is, for customers from overseas, a profound source of reassurance. What we have valued is not only the facilities, but the experience itself, being able to consult without anxiety and proceed with full understanding. This recognition tells us that commitment has carried across borders. Expectations for Japanese medical care will only grow, and we will keep rising to meet them so that we remain the choice of customers worldwide.”
About SBC Medical Group Holdings Incorporated
SBC Medical is a Medical Services Organization providing management support across a wide range of healthcare fields, including advanced aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, hair loss treatment (AGA), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose “Contributing to the well-being of people around the world through medical innovation,” SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.
For more information, visit https://sbc-holdings.com
For more insights and updates from SBC Medical, follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company’s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company’s control. These forward-looking statements reflect the Company’s current views with respect to, among other things, the Company’s plans and strategies for service expansion; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” “targets” or “hopes” or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading “Risk Factors” and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261105535025/en/
Contacts
Hikaru Fukui / Head of IR Department; E-mail: ir@sbc-holdings.com
Akiko Wakiyama / Chief Public Relations Officer; E-mail: pr@sbc.or.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LPs Expect Private Markets Managers to Level Up in 2027: SS&C Intralinks Survey5.11.2026 16:00:00 EET | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced the publication of the 2027 LP Survey. In association with Reuters Insights, SS&C Intralinks surveyed 400 professionals working in private markets, including 370 limited partners and allocators, to understand how the alternative investments market will change in the next 12 months.* “Alternatives once again delivered in 2026, and LPs are still committing capital, but their expectations of managers continue to rise,” said Ken Bisconti, general manager of SS&C Intralinks. “Technology and data capabilities now rank among the most important criteria for selecting managers, alongside investment strategy. Performance alone is no longer enough. For nearly one-third of allocators, a credible artificial intelligence (AI) strategy is now a prerequisite for allocating capital to a manager.” Key findings from the report include: Alternatives portfolios continue to outperform. 62% of respondents said their portfolios exceeded expectati
Hyperice Unveils Normatec Elite Heat Legs: Integrated Heat Meets Dynamic Air Compression in a New Fully Wireless Design5.11.2026 16:00:00 EET | Press release
Hyperice, a high-performance wellness brand, today announced the launch of Normatec Elite Heat Legs, the newest innovation in the award-winning Normatec line and the first Normatec product to incorporate heat directly into its line of dynamic air compression therapy. As the 2024 launch of Normatec Elite signified a transformative leap forward in recovery technology, Elite Heat demonstrates Hyperice’s relentless commitment to offering athletes and wellness enthusiasts alike the most comprehensive and intuitive recovery experiences in the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105782891/en/ Normatec Elite Heat demonstrates Hyperice’s relentless commitment to offering athletes and wellness enthusiasts alike the most comprehensive and intuitive recovery experiences in the world. “Innovation has always been at the forefront of everything we do,” said Jim Huether, CEO of Hyperice. “Heat and dynamic air compressio
European Commission expands license for Alfasigma’s Jyseleca ® (filgotinib) with approval of new indication, treatment of adults with axial spondylarthritis5.11.2026 16:00:00 EET | Press release
The information contained within this press release is for the purpose of scientific exchange. It is intended for scientific, financial and investor media only. Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Commission (EC) has approved an additional indication to Jyseleca® (filgotinib) 200 mg and 100 mg film-coated tablets, an oral once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. A submission for UK approval has been made to the Medicines and Healthcare products Regulatory Agency (MHRA) and is under review. The European Commission’s approval is based on data that support a favourable benefit-risk profile for filgotinib, including efficacy and safety fin
Mohammed Bin Rashid Library to host third Dubai International Library and Publishing Summit under the theme “Architecture of Trust: AI and the Future of Knowledge Institutions”5.11.2026 15:43:00 EET | Press release
Mohammed Bin Rashid Library has announced the third edition of the Dubai International Library and Publishing Summit, taking place on 16 and 17 November 2026 under the theme “The Architecture of Trust: AI and the Future of Knowledge Institutions”. The Summit will bring together experts from libraries, museums, publishing houses, universities, research centres, cultural institutions and the technology sector worldwide to explore the future of knowledge institutions in the age of artificial intelligence. This year’s edition will feature more than 50 speakers representing over 40 organisations, across more than 20 panel discussions, keynote addresses and specialist workshops. The Summit will bring together local and international institutions, including leading UAE-based entities such as Zayed National Museum, the Technology Innovation Institute (TII) and Natural History Museum in Abu Dhabi, alongside international institutions such as the Leverhulme Centre for the Future of Intelligence
Current Chemicals Expands U.S. Production of Rare-Earth Fluorides With New Investment From Momentum Global Ventures5.11.2026 15:14:00 EET | Press release
Current Chemicals, Inc. (“CCI”), one of the few U.S. companies converting separated rare-earth oxides into the fluorides used to make rare-earth metals and magnets, today announced an additional investment from its lead shareholder, Momentum Global Ventures (“MGV”). The investment will significantly increase CCI’s production of neodymium fluoride, dysprosium fluoride, and other key rare-earth fluorides in Cleveland. The funding adds infrastructure, equipment and engineering staff for fluorides of neodymium, dysprosium, terbium, gadolinium, yttrium, scandium, lanthanum, and lithium for reducing light rare-earths to metal: key inputs for permanent magnets, advanced coatings, and alloys. Neodymium fluoride and dysprosium fluoride are key feedstocks for the metal at the core of high-performance magnets in electric motors, wind turbines and defense systems. Most processing capacity today is in China and, with U.S. defense sourcing rules tightening from January 2027, domestic conversion is o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom